nodes	percent_of_prediction	percent_of_DWPC	metapath
Disopyramide—ORM1—Gefitinib—lung cancer	0.188	0.298	CbGbCtD
Disopyramide—ORM1—Erlotinib—lung cancer	0.111	0.176	CbGbCtD
Disopyramide—SLC22A2—Vinblastine—lung cancer	0.0738	0.117	CbGbCtD
Disopyramide—SLC22A2—Cisplatin—lung cancer	0.0676	0.107	CbGbCtD
Disopyramide—CYP3A4—Topotecan—lung cancer	0.0271	0.0429	CbGbCtD
Disopyramide—CYP3A4—Gefitinib—lung cancer	0.0248	0.0393	CbGbCtD
Disopyramide—CYP3A4—Teniposide—lung cancer	0.024	0.0381	CbGbCtD
Disopyramide—CYP3A4—Vinorelbine—lung cancer	0.0191	0.0302	CbGbCtD
Disopyramide—CYP3A4—Crizotinib—lung cancer	0.0152	0.0241	CbGbCtD
Disopyramide—CYP3A4—Erlotinib—lung cancer	0.0147	0.0232	CbGbCtD
Disopyramide—CYP3A4—Paclitaxel—lung cancer	0.0134	0.0212	CbGbCtD
Disopyramide—CYP3A4—Irinotecan—lung cancer	0.0132	0.021	CbGbCtD
Disopyramide—CYP3A4—Vinblastine—lung cancer	0.0118	0.0186	CbGbCtD
Disopyramide—CYP3A4—Etoposide—lung cancer	0.0106	0.0168	CbGbCtD
Disopyramide—CYP3A4—Docetaxel—lung cancer	0.0097	0.0154	CbGbCtD
Disopyramide—CYP3A4—Doxorubicin—lung cancer	0.00723	0.0115	CbGbCtD
Disopyramide—Levomethadyl Acetate—CHRNB4—lung cancer	0.00223	0.486	CrCbGaD
Disopyramide—Levomethadyl Acetate—CHRNA3—lung cancer	0.00155	0.337	CrCbGaD
Disopyramide—Fesoterodine—ABCB1—lung cancer	0.000667	0.146	CrCbGaD
Disopyramide—Loss of consciousness—Paclitaxel—lung cancer	0.000255	0.00102	CcSEcCtD
Disopyramide—Diplopia—Doxorubicin—lung cancer	0.000254	0.00102	CcSEcCtD
Disopyramide—Hyperhidrosis—Cisplatin—lung cancer	0.000254	0.00102	CcSEcCtD
Disopyramide—Paraesthesia—Gemcitabine—lung cancer	0.000254	0.00102	CcSEcCtD
Disopyramide—Asthenia—Vinorelbine—lung cancer	0.000252	0.00101	CcSEcCtD
Disopyramide—Decreased appetite—Irinotecan—lung cancer	0.000252	0.00101	CcSEcCtD
Disopyramide—Arrhythmia—Docetaxel—lung cancer	0.000252	0.00101	CcSEcCtD
Disopyramide—Dyspnoea—Gemcitabine—lung cancer	0.000252	0.00101	CcSEcCtD
Disopyramide—Chest pain—Etoposide—lung cancer	0.000252	0.00101	CcSEcCtD
Disopyramide—Nausea—Vinblastine—lung cancer	0.000251	0.00101	CcSEcCtD
Disopyramide—Somnolence—Gemcitabine—lung cancer	0.000251	0.00101	CcSEcCtD
Disopyramide—Anorexia—Cisplatin—lung cancer	0.000251	0.00101	CcSEcCtD
Disopyramide—Fatigue—Irinotecan—lung cancer	0.00025	0.001	CcSEcCtD
Disopyramide—Pruritus—Vinorelbine—lung cancer	0.000249	0.000996	CcSEcCtD
Disopyramide—Discomfort—Etoposide—lung cancer	0.000249	0.000996	CcSEcCtD
Disopyramide—Pain—Irinotecan—lung cancer	0.000248	0.000993	CcSEcCtD
Disopyramide—Constipation—Irinotecan—lung cancer	0.000248	0.000993	CcSEcCtD
Disopyramide—Chest pain—Paclitaxel—lung cancer	0.000247	0.000988	CcSEcCtD
Disopyramide—Hypotension—Cisplatin—lung cancer	0.000246	0.000985	CcSEcCtD
Disopyramide—Decreased appetite—Gemcitabine—lung cancer	0.000245	0.000984	CcSEcCtD
Disopyramide—Nausea—Topotecan—lung cancer	0.000244	0.000978	CcSEcCtD
Disopyramide—Discomfort—Paclitaxel—lung cancer	0.000244	0.000976	CcSEcCtD
Disopyramide—Fatigue—Gemcitabine—lung cancer	0.000243	0.000975	CcSEcCtD
Disopyramide—Confusional state—Etoposide—lung cancer	0.000243	0.000974	CcSEcCtD
Disopyramide—Cardiac arrest—Doxorubicin—lung cancer	0.000242	0.000969	CcSEcCtD
Disopyramide—Pain—Gemcitabine—lung cancer	0.000241	0.000968	CcSEcCtD
Disopyramide—Constipation—Gemcitabine—lung cancer	0.000241	0.000968	CcSEcCtD
Disopyramide—Nausea—Erlotinib—lung cancer	0.000241	0.000968	CcSEcCtD
Disopyramide—Dry mouth—Paclitaxel—lung cancer	0.000241	0.000966	CcSEcCtD
Disopyramide—Diarrhoea—Vinorelbine—lung cancer	0.000241	0.000964	CcSEcCtD
Disopyramide—Dysgeusia—Docetaxel—lung cancer	0.00024	0.000963	CcSEcCtD
Disopyramide—Feeling abnormal—Irinotecan—lung cancer	0.000239	0.000957	CcSEcCtD
Disopyramide—Confusional state—Paclitaxel—lung cancer	0.000238	0.000955	CcSEcCtD
Disopyramide—Blood creatinine increased—Doxorubicin—lung cancer	0.000238	0.000955	CcSEcCtD
Disopyramide—Dysuria—Methotrexate—lung cancer	0.000238	0.000952	CcSEcCtD
Disopyramide—Neutropenia—Methotrexate—lung cancer	0.000238	0.000952	CcSEcCtD
Disopyramide—Oedema—Paclitaxel—lung cancer	0.000236	0.000947	CcSEcCtD
Disopyramide—Paraesthesia—Cisplatin—lung cancer	0.000236	0.000947	CcSEcCtD
Disopyramide—Thrombocytopenia—Etoposide—lung cancer	0.000236	0.000946	CcSEcCtD
Disopyramide—Dyspnoea—Cisplatin—lung cancer	0.000235	0.00094	CcSEcCtD
Disopyramide—Skin disorder—Etoposide—lung cancer	0.000234	0.000938	CcSEcCtD
Disopyramide—Erectile dysfunction—Methotrexate—lung cancer	0.000234	0.000937	CcSEcCtD
Disopyramide—Hyperhidrosis—Etoposide—lung cancer	0.000233	0.000934	CcSEcCtD
Disopyramide—Feeling abnormal—Gemcitabine—lung cancer	0.000233	0.000932	CcSEcCtD
Disopyramide—Shock—Paclitaxel—lung cancer	0.000233	0.000932	CcSEcCtD
Disopyramide—Dizziness—Vinorelbine—lung cancer	0.000232	0.000931	CcSEcCtD
Disopyramide—Abdominal pain upper—Doxorubicin—lung cancer	0.000232	0.000931	CcSEcCtD
Disopyramide—Hypokalaemia—Doxorubicin—lung cancer	0.000232	0.000928	CcSEcCtD
Disopyramide—Thrombocytopenia—Paclitaxel—lung cancer	0.000231	0.000927	CcSEcCtD
Disopyramide—Anorexia—Etoposide—lung cancer	0.00023	0.000921	CcSEcCtD
Disopyramide—Skin disorder—Paclitaxel—lung cancer	0.00023	0.00092	CcSEcCtD
Disopyramide—Body temperature increased—Irinotecan—lung cancer	0.000229	0.000918	CcSEcCtD
Disopyramide—Decreased appetite—Cisplatin—lung cancer	0.000229	0.000917	CcSEcCtD
Disopyramide—Hyperhidrosis—Paclitaxel—lung cancer	0.000229	0.000916	CcSEcCtD
Disopyramide—Drowsiness—Methotrexate—lung cancer	0.000226	0.000907	CcSEcCtD
Disopyramide—Depression—Methotrexate—lung cancer	0.000226	0.000905	CcSEcCtD
Disopyramide—Anorexia—Paclitaxel—lung cancer	0.000225	0.000903	CcSEcCtD
Disopyramide—Hypotension—Etoposide—lung cancer	0.000225	0.000903	CcSEcCtD
Disopyramide—Pain—Cisplatin—lung cancer	0.000225	0.000902	CcSEcCtD
Disopyramide—Muscular weakness—Doxorubicin—lung cancer	0.000224	0.000899	CcSEcCtD
Disopyramide—Vomiting—Vinorelbine—lung cancer	0.000223	0.000895	CcSEcCtD
Disopyramide—Body temperature increased—Gemcitabine—lung cancer	0.000223	0.000894	CcSEcCtD
Disopyramide—Rash—Vinorelbine—lung cancer	0.000222	0.000888	CcSEcCtD
Disopyramide—Dermatitis—Vinorelbine—lung cancer	0.000221	0.000887	CcSEcCtD
Disopyramide—Abdominal distension—Doxorubicin—lung cancer	0.000221	0.000887	CcSEcCtD
Disopyramide—Hypotension—Paclitaxel—lung cancer	0.000221	0.000885	CcSEcCtD
Disopyramide—Headache—Vinorelbine—lung cancer	0.00022	0.000882	CcSEcCtD
Disopyramide—Syncope—Docetaxel—lung cancer	0.00022	0.000882	CcSEcCtD
Disopyramide—Feeling abnormal—Cisplatin—lung cancer	0.000217	0.000869	CcSEcCtD
Disopyramide—Paraesthesia—Etoposide—lung cancer	0.000217	0.000868	CcSEcCtD
Disopyramide—Loss of consciousness—Docetaxel—lung cancer	0.000216	0.000865	CcSEcCtD
Disopyramide—Dyspnoea—Etoposide—lung cancer	0.000215	0.000861	CcSEcCtD
Disopyramide—Somnolence—Etoposide—lung cancer	0.000214	0.000859	CcSEcCtD
Disopyramide—Insomnia—Paclitaxel—lung cancer	0.000214	0.000857	CcSEcCtD
Disopyramide—Paraesthesia—Paclitaxel—lung cancer	0.000212	0.000851	CcSEcCtD
Disopyramide—Agranulocytosis—Methotrexate—lung cancer	0.000211	0.000847	CcSEcCtD
Disopyramide—Dyspnoea—Paclitaxel—lung cancer	0.000211	0.000845	CcSEcCtD
Disopyramide—Somnolence—Paclitaxel—lung cancer	0.00021	0.000842	CcSEcCtD
Disopyramide—Decreased appetite—Etoposide—lung cancer	0.00021	0.00084	CcSEcCtD
Disopyramide—Chest pain—Docetaxel—lung cancer	0.000209	0.000838	CcSEcCtD
Disopyramide—Nausea—Vinorelbine—lung cancer	0.000209	0.000837	CcSEcCtD
Disopyramide—Dyspepsia—Paclitaxel—lung cancer	0.000208	0.000834	CcSEcCtD
Disopyramide—Body temperature increased—Cisplatin—lung cancer	0.000208	0.000834	CcSEcCtD
Disopyramide—Asthenia—Irinotecan—lung cancer	0.000208	0.000833	CcSEcCtD
Disopyramide—Fatigue—Etoposide—lung cancer	0.000208	0.000833	CcSEcCtD
Disopyramide—Pain—Etoposide—lung cancer	0.000206	0.000826	CcSEcCtD
Disopyramide—Constipation—Etoposide—lung cancer	0.000206	0.000826	CcSEcCtD
Disopyramide—Neutropenia—Doxorubicin—lung cancer	0.000206	0.000824	CcSEcCtD
Disopyramide—Dysuria—Doxorubicin—lung cancer	0.000206	0.000824	CcSEcCtD
Disopyramide—Decreased appetite—Paclitaxel—lung cancer	0.000206	0.000823	CcSEcCtD
Disopyramide—Dry mouth—Docetaxel—lung cancer	0.000204	0.000819	CcSEcCtD
Disopyramide—Fatigue—Paclitaxel—lung cancer	0.000204	0.000817	CcSEcCtD
Disopyramide—Hepatitis—Methotrexate—lung cancer	0.000203	0.000815	CcSEcCtD
Disopyramide—Pollakiuria—Doxorubicin—lung cancer	0.000203	0.000814	CcSEcCtD
Disopyramide—Asthenia—Gemcitabine—lung cancer	0.000203	0.000812	CcSEcCtD
Disopyramide—Constipation—Paclitaxel—lung cancer	0.000202	0.00081	CcSEcCtD
Disopyramide—Pain—Paclitaxel—lung cancer	0.000202	0.00081	CcSEcCtD
Disopyramide—Confusional state—Docetaxel—lung cancer	0.000202	0.00081	CcSEcCtD
Disopyramide—Oedema—Docetaxel—lung cancer	0.0002	0.000803	CcSEcCtD
Disopyramide—Weight increased—Doxorubicin—lung cancer	0.0002	0.000802	CcSEcCtD
Disopyramide—Pruritus—Gemcitabine—lung cancer	0.0002	0.0008	CcSEcCtD
Disopyramide—Feeling abnormal—Etoposide—lung cancer	0.000199	0.000796	CcSEcCtD
Disopyramide—Diarrhoea—Irinotecan—lung cancer	0.000198	0.000795	CcSEcCtD
Disopyramide—Shock—Docetaxel—lung cancer	0.000197	0.00079	CcSEcCtD
Disopyramide—Thrombocytopenia—Docetaxel—lung cancer	0.000196	0.000786	CcSEcCtD
Disopyramide—Drowsiness—Doxorubicin—lung cancer	0.000196	0.000786	CcSEcCtD
Disopyramide—Feeling abnormal—Paclitaxel—lung cancer	0.000195	0.000781	CcSEcCtD
Disopyramide—Skin disorder—Docetaxel—lung cancer	0.000195	0.00078	CcSEcCtD
Disopyramide—Diarrhoea—Gemcitabine—lung cancer	0.000193	0.000774	CcSEcCtD
Disopyramide—Dizziness—Irinotecan—lung cancer	0.000192	0.000768	CcSEcCtD
Disopyramide—Urticaria—Etoposide—lung cancer	0.000192	0.000768	CcSEcCtD
Disopyramide—Anorexia—Docetaxel—lung cancer	0.000191	0.000765	CcSEcCtD
Disopyramide—Body temperature increased—Etoposide—lung cancer	0.000191	0.000764	CcSEcCtD
Disopyramide—Asthenia—Cisplatin—lung cancer	0.000189	0.000757	CcSEcCtD
Disopyramide—Urticaria—Paclitaxel—lung cancer	0.000188	0.000753	CcSEcCtD
Disopyramide—Hypotension—Docetaxel—lung cancer	0.000187	0.00075	CcSEcCtD
Disopyramide—Body temperature increased—Paclitaxel—lung cancer	0.000187	0.000749	CcSEcCtD
Disopyramide—Vomiting—Irinotecan—lung cancer	0.000184	0.000739	CcSEcCtD
Disopyramide—Agranulocytosis—Doxorubicin—lung cancer	0.000183	0.000733	CcSEcCtD
Disopyramide—Rash—Irinotecan—lung cancer	0.000183	0.000732	CcSEcCtD
Disopyramide—Dermatitis—Irinotecan—lung cancer	0.000183	0.000732	CcSEcCtD
Disopyramide—Headache—Irinotecan—lung cancer	0.000182	0.000728	CcSEcCtD
Disopyramide—Insomnia—Docetaxel—lung cancer	0.000181	0.000726	CcSEcCtD
Disopyramide—Diarrhoea—Cisplatin—lung cancer	0.00018	0.000722	CcSEcCtD
Disopyramide—Paraesthesia—Docetaxel—lung cancer	0.00018	0.000721	CcSEcCtD
Disopyramide—Vomiting—Gemcitabine—lung cancer	0.00018	0.000719	CcSEcCtD
Disopyramide—Bradycardia—Doxorubicin—lung cancer	0.000179	0.000718	CcSEcCtD
Disopyramide—Dyspnoea—Docetaxel—lung cancer	0.000179	0.000716	CcSEcCtD
Disopyramide—Somnolence—Docetaxel—lung cancer	0.000178	0.000714	CcSEcCtD
Disopyramide—Rash—Gemcitabine—lung cancer	0.000178	0.000713	CcSEcCtD
Disopyramide—Dermatitis—Gemcitabine—lung cancer	0.000178	0.000713	CcSEcCtD
Disopyramide—Headache—Gemcitabine—lung cancer	0.000177	0.000709	CcSEcCtD
Disopyramide—Dyspepsia—Docetaxel—lung cancer	0.000176	0.000707	CcSEcCtD
Disopyramide—Hepatitis—Doxorubicin—lung cancer	0.000176	0.000705	CcSEcCtD
Disopyramide—Hypoaesthesia—Doxorubicin—lung cancer	0.000175	0.000702	CcSEcCtD
Disopyramide—Decreased appetite—Docetaxel—lung cancer	0.000174	0.000698	CcSEcCtD
Disopyramide—Dysgeusia—Methotrexate—lung cancer	0.000173	0.000694	CcSEcCtD
Disopyramide—Asthenia—Etoposide—lung cancer	0.000173	0.000693	CcSEcCtD
Disopyramide—Fatigue—Docetaxel—lung cancer	0.000173	0.000692	CcSEcCtD
Disopyramide—Nausea—Irinotecan—lung cancer	0.000172	0.00069	CcSEcCtD
Disopyramide—Constipation—Docetaxel—lung cancer	0.000171	0.000687	CcSEcCtD
Disopyramide—Pain—Docetaxel—lung cancer	0.000171	0.000687	CcSEcCtD
Disopyramide—Pruritus—Etoposide—lung cancer	0.000171	0.000684	CcSEcCtD
Disopyramide—Asthenia—Paclitaxel—lung cancer	0.00017	0.00068	CcSEcCtD
Disopyramide—Nausea—Gemcitabine—lung cancer	0.000168	0.000672	CcSEcCtD
Disopyramide—Vomiting—Cisplatin—lung cancer	0.000167	0.000671	CcSEcCtD
Disopyramide—Pruritus—Paclitaxel—lung cancer	0.000167	0.00067	CcSEcCtD
Disopyramide—Vision blurred—Methotrexate—lung cancer	0.000167	0.000668	CcSEcCtD
Disopyramide—Rash—Cisplatin—lung cancer	0.000166	0.000665	CcSEcCtD
Disopyramide—Dermatitis—Cisplatin—lung cancer	0.000166	0.000664	CcSEcCtD
Disopyramide—Feeling abnormal—Docetaxel—lung cancer	0.000165	0.000662	CcSEcCtD
Disopyramide—Diarrhoea—Etoposide—lung cancer	0.000165	0.000661	CcSEcCtD
Disopyramide—Ill-defined disorder—Methotrexate—lung cancer	0.000164	0.000658	CcSEcCtD
Disopyramide—Diarrhoea—Paclitaxel—lung cancer	0.000162	0.000648	CcSEcCtD
Disopyramide—Malaise—Methotrexate—lung cancer	0.00016	0.000639	CcSEcCtD
Disopyramide—Dizziness—Etoposide—lung cancer	0.000159	0.000639	CcSEcCtD
Disopyramide—Vertigo—Methotrexate—lung cancer	0.000159	0.000637	CcSEcCtD
Disopyramide—Body temperature increased—Docetaxel—lung cancer	0.000158	0.000635	CcSEcCtD
Disopyramide—Arrhythmia—Doxorubicin—lung cancer	0.000157	0.00063	CcSEcCtD
Disopyramide—Dizziness—Paclitaxel—lung cancer	0.000156	0.000626	CcSEcCtD
Disopyramide—Nausea—Cisplatin—lung cancer	0.000156	0.000626	CcSEcCtD
Disopyramide—Vomiting—Etoposide—lung cancer	0.000153	0.000614	CcSEcCtD
Disopyramide—Rash—Etoposide—lung cancer	0.000152	0.000609	CcSEcCtD
Disopyramide—Dermatitis—Etoposide—lung cancer	0.000152	0.000609	CcSEcCtD
Disopyramide—Headache—Etoposide—lung cancer	0.000151	0.000605	CcSEcCtD
Disopyramide—Flatulence—Doxorubicin—lung cancer	0.000151	0.000605	CcSEcCtD
Disopyramide—Chest pain—Methotrexate—lung cancer	0.000151	0.000604	CcSEcCtD
Disopyramide—Tension—Doxorubicin—lung cancer	0.00015	0.000603	CcSEcCtD
Disopyramide—Vomiting—Paclitaxel—lung cancer	0.00015	0.000602	CcSEcCtD
Disopyramide—Dysgeusia—Doxorubicin—lung cancer	0.00015	0.000601	CcSEcCtD
Disopyramide—Rash—Paclitaxel—lung cancer	0.000149	0.000597	CcSEcCtD
Disopyramide—Dermatitis—Paclitaxel—lung cancer	0.000149	0.000597	CcSEcCtD
Disopyramide—Discomfort—Methotrexate—lung cancer	0.000149	0.000596	CcSEcCtD
Disopyramide—Nervousness—Doxorubicin—lung cancer	0.000149	0.000596	CcSEcCtD
Disopyramide—Headache—Paclitaxel—lung cancer	0.000148	0.000593	CcSEcCtD
Disopyramide—Confusional state—Methotrexate—lung cancer	0.000146	0.000584	CcSEcCtD
Disopyramide—Vision blurred—Doxorubicin—lung cancer	0.000144	0.000579	CcSEcCtD
Disopyramide—Asthenia—Docetaxel—lung cancer	0.000144	0.000576	CcSEcCtD
Disopyramide—Nausea—Etoposide—lung cancer	0.000143	0.000574	CcSEcCtD
Disopyramide—Methadone—ABCB1—lung cancer	0.000142	0.0311	CrCbGaD
Disopyramide—Ill-defined disorder—Doxorubicin—lung cancer	0.000142	0.00057	CcSEcCtD
Disopyramide—Pruritus—Docetaxel—lung cancer	0.000142	0.000568	CcSEcCtD
Disopyramide—Thrombocytopenia—Methotrexate—lung cancer	0.000141	0.000567	CcSEcCtD
Disopyramide—Nausea—Paclitaxel—lung cancer	0.00014	0.000563	CcSEcCtD
Disopyramide—Skin disorder—Methotrexate—lung cancer	0.00014	0.000562	CcSEcCtD
Disopyramide—Hyperhidrosis—Methotrexate—lung cancer	0.00014	0.000559	CcSEcCtD
Disopyramide—Malaise—Doxorubicin—lung cancer	0.000138	0.000554	CcSEcCtD
Disopyramide—Vertigo—Doxorubicin—lung cancer	0.000138	0.000552	CcSEcCtD
Disopyramide—Anorexia—Methotrexate—lung cancer	0.000138	0.000552	CcSEcCtD
Disopyramide—Syncope—Doxorubicin—lung cancer	0.000137	0.000551	CcSEcCtD
Disopyramide—Diarrhoea—Docetaxel—lung cancer	0.000137	0.000549	CcSEcCtD
Disopyramide—Hypotension—Methotrexate—lung cancer	0.000135	0.000541	CcSEcCtD
Disopyramide—Loss of consciousness—Doxorubicin—lung cancer	0.000135	0.00054	CcSEcCtD
Disopyramide—Dizziness—Docetaxel—lung cancer	0.000133	0.000531	CcSEcCtD
Disopyramide—Insomnia—Methotrexate—lung cancer	0.000131	0.000523	CcSEcCtD
Disopyramide—Chest pain—Doxorubicin—lung cancer	0.00013	0.000523	CcSEcCtD
Disopyramide—Paraesthesia—Methotrexate—lung cancer	0.00013	0.00052	CcSEcCtD
Disopyramide—Discomfort—Doxorubicin—lung cancer	0.000129	0.000516	CcSEcCtD
Disopyramide—Dyspnoea—Methotrexate—lung cancer	0.000129	0.000516	CcSEcCtD
Disopyramide—Somnolence—Methotrexate—lung cancer	0.000128	0.000514	CcSEcCtD
Disopyramide—Dry mouth—Doxorubicin—lung cancer	0.000128	0.000511	CcSEcCtD
Disopyramide—Vomiting—Docetaxel—lung cancer	0.000127	0.000511	CcSEcCtD
Disopyramide—Dyspepsia—Methotrexate—lung cancer	0.000127	0.000509	CcSEcCtD
Disopyramide—Rash—Docetaxel—lung cancer	0.000126	0.000506	CcSEcCtD
Disopyramide—Dermatitis—Docetaxel—lung cancer	0.000126	0.000506	CcSEcCtD
Disopyramide—Confusional state—Doxorubicin—lung cancer	0.000126	0.000505	CcSEcCtD
Disopyramide—Decreased appetite—Methotrexate—lung cancer	0.000126	0.000503	CcSEcCtD
Disopyramide—Headache—Docetaxel—lung cancer	0.000126	0.000503	CcSEcCtD
Disopyramide—Oedema—Doxorubicin—lung cancer	0.000125	0.000501	CcSEcCtD
Disopyramide—Fatigue—Methotrexate—lung cancer	0.000125	0.000499	CcSEcCtD
Disopyramide—Pain—Methotrexate—lung cancer	0.000124	0.000495	CcSEcCtD
Disopyramide—Shock—Doxorubicin—lung cancer	0.000123	0.000493	CcSEcCtD
Disopyramide—Thrombocytopenia—Doxorubicin—lung cancer	0.000122	0.000491	CcSEcCtD
Disopyramide—Skin disorder—Doxorubicin—lung cancer	0.000121	0.000487	CcSEcCtD
Disopyramide—Hyperhidrosis—Doxorubicin—lung cancer	0.000121	0.000484	CcSEcCtD
Disopyramide—Anorexia—Doxorubicin—lung cancer	0.000119	0.000478	CcSEcCtD
Disopyramide—Nausea—Docetaxel—lung cancer	0.000119	0.000477	CcSEcCtD
Disopyramide—Feeling abnormal—Methotrexate—lung cancer	0.000119	0.000477	CcSEcCtD
Disopyramide—Hypotension—Doxorubicin—lung cancer	0.000117	0.000468	CcSEcCtD
Disopyramide—Urticaria—Methotrexate—lung cancer	0.000115	0.00046	CcSEcCtD
Disopyramide—Body temperature increased—Methotrexate—lung cancer	0.000114	0.000457	CcSEcCtD
Disopyramide—Insomnia—Doxorubicin—lung cancer	0.000113	0.000453	CcSEcCtD
Disopyramide—Paraesthesia—Doxorubicin—lung cancer	0.000112	0.00045	CcSEcCtD
Disopyramide—Dyspnoea—Doxorubicin—lung cancer	0.000112	0.000447	CcSEcCtD
Disopyramide—Somnolence—Doxorubicin—lung cancer	0.000111	0.000445	CcSEcCtD
Disopyramide—Dyspepsia—Doxorubicin—lung cancer	0.00011	0.000441	CcSEcCtD
Disopyramide—Decreased appetite—Doxorubicin—lung cancer	0.000109	0.000436	CcSEcCtD
Disopyramide—Fatigue—Doxorubicin—lung cancer	0.000108	0.000432	CcSEcCtD
Disopyramide—Constipation—Doxorubicin—lung cancer	0.000107	0.000429	CcSEcCtD
Disopyramide—Pain—Doxorubicin—lung cancer	0.000107	0.000429	CcSEcCtD
Disopyramide—Asthenia—Methotrexate—lung cancer	0.000104	0.000415	CcSEcCtD
Disopyramide—Feeling abnormal—Doxorubicin—lung cancer	0.000103	0.000413	CcSEcCtD
Disopyramide—Pruritus—Methotrexate—lung cancer	0.000102	0.000409	CcSEcCtD
Disopyramide—Urticaria—Doxorubicin—lung cancer	9.94e-05	0.000398	CcSEcCtD
Disopyramide—Body temperature increased—Doxorubicin—lung cancer	9.89e-05	0.000396	CcSEcCtD
Disopyramide—Diarrhoea—Methotrexate—lung cancer	9.88e-05	0.000396	CcSEcCtD
Disopyramide—Dizziness—Methotrexate—lung cancer	9.55e-05	0.000383	CcSEcCtD
Disopyramide—Vomiting—Methotrexate—lung cancer	9.18e-05	0.000368	CcSEcCtD
Disopyramide—Rash—Methotrexate—lung cancer	9.11e-05	0.000365	CcSEcCtD
Disopyramide—Dermatitis—Methotrexate—lung cancer	9.1e-05	0.000365	CcSEcCtD
Disopyramide—Headache—Methotrexate—lung cancer	9.05e-05	0.000363	CcSEcCtD
Disopyramide—Asthenia—Doxorubicin—lung cancer	8.97e-05	0.00036	CcSEcCtD
Disopyramide—Pruritus—Doxorubicin—lung cancer	8.85e-05	0.000355	CcSEcCtD
Disopyramide—Nausea—Methotrexate—lung cancer	8.58e-05	0.000344	CcSEcCtD
Disopyramide—Diarrhoea—Doxorubicin—lung cancer	8.56e-05	0.000343	CcSEcCtD
Disopyramide—Dizziness—Doxorubicin—lung cancer	8.27e-05	0.000331	CcSEcCtD
Disopyramide—Vomiting—Doxorubicin—lung cancer	7.95e-05	0.000319	CcSEcCtD
Disopyramide—Rash—Doxorubicin—lung cancer	7.89e-05	0.000316	CcSEcCtD
Disopyramide—Dermatitis—Doxorubicin—lung cancer	7.88e-05	0.000316	CcSEcCtD
Disopyramide—Headache—Doxorubicin—lung cancer	7.84e-05	0.000314	CcSEcCtD
Disopyramide—Nausea—Doxorubicin—lung cancer	7.43e-05	0.000298	CcSEcCtD
Disopyramide—CHRM2—GPCR downstream signaling—CXCL8—lung cancer	1.28e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HES1—lung cancer	1.28e-05	0.000112	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HES1—lung cancer	1.27e-05	0.000111	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HES1—lung cancer	1.26e-05	0.00011	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTA2—lung cancer	1.26e-05	0.00011	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—RAF1—lung cancer	1.25e-05	0.000109	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—RAF1—lung cancer	1.25e-05	0.000109	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—POMC—lung cancer	1.24e-05	0.000109	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—IL2—lung cancer	1.24e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—RAF1—lung cancer	1.24e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—IL2—lung cancer	1.23e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—APOA1—lung cancer	1.23e-05	0.000108	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CB—lung cancer	1.22e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—IL2—lung cancer	1.22e-05	0.000107	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CB—lung cancer	1.22e-05	0.000106	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CG—lung cancer	1.22e-05	0.000106	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTA1—lung cancer	1.21e-05	0.000106	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—CREBBP—lung cancer	1.21e-05	0.000106	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CB—lung cancer	1.21e-05	0.000105	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCC3—lung cancer	1.2e-05	0.000105	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—CXCL8—lung cancer	1.18e-05	0.000103	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—CXCL8—lung cancer	1.17e-05	0.000102	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ERBB3—lung cancer	1.17e-05	0.000102	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ERBB3—lung cancer	1.16e-05	0.000102	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AKR1C1—lung cancer	1.16e-05	0.000101	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—CXCL8—lung cancer	1.16e-05	0.000101	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—POMC—lung cancer	1.16e-05	0.000101	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ERBB3—lung cancer	1.15e-05	0.000101	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CD—lung cancer	1.15e-05	0.0001	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—ALB—lung cancer	1.13e-05	9.89e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—CREBBP—lung cancer	1.13e-05	9.85e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—UGT1A1—lung cancer	1.13e-05	9.84e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CG—lung cancer	1.12e-05	9.81e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL2—lung cancer	1.12e-05	9.81e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL2—lung cancer	1.12e-05	9.78e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TERT—lung cancer	1.12e-05	9.77e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TERT—lung cancer	1.12e-05	9.74e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL2—lung cancer	1.11e-05	9.68e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TERT—lung cancer	1.11e-05	9.65e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—FGFR1—lung cancer	1.09e-05	9.49e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GNG11—lung cancer	1.09e-05	9.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—FGFR1—lung cancer	1.08e-05	9.46e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—FGFR1—lung cancer	1.07e-05	9.37e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HIF1A—lung cancer	1.07e-05	9.34e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—POMC—lung cancer	1.07e-05	9.34e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CD—lung cancer	1.07e-05	9.34e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HIF1A—lung cancer	1.07e-05	9.31e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HIF1A—lung cancer	1.06e-05	9.22e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—ALB—lung cancer	1.06e-05	9.22e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—CREBBP—lung cancer	1.04e-05	9.1e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALDOA—lung cancer	1.03e-05	9.03e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APOA1—lung cancer	1.03e-05	9.02e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APOA1—lung cancer	1.03e-05	8.99e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KDR—lung cancer	1.02e-05	8.94e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KDR—lung cancer	1.02e-05	8.91e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APOA1—lung cancer	1.02e-05	8.9e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KDR—lung cancer	1.01e-05	8.82e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NCOA3—lung cancer	1e-05	8.77e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CB—lung cancer	1e-05	8.73e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTGS2—lung cancer	9.92e-06	8.65e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CD—lung cancer	9.89e-06	8.63e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ADCY1—lung cancer	9.77e-06	8.53e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCG2—lung cancer	9.77e-06	8.53e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—ALB—lung cancer	9.76e-06	8.52e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—HPGDS—lung cancer	9.59e-06	8.36e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ENO2—lung cancer	9.59e-06	8.36e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PPP2R1B—lung cancer	9.53e-06	8.31e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KIT—lung cancer	9.44e-06	8.23e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CG—lung cancer	9.44e-06	8.23e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—APC—lung cancer	9.44e-06	8.23e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—NRAS—lung cancer	9.44e-06	8.23e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—APC—lung cancer	9.41e-06	8.21e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CG—lung cancer	9.41e-06	8.21e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KIT—lung cancer	9.41e-06	8.21e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—NRAS—lung cancer	9.41e-06	8.21e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CB—lung cancer	9.33e-06	8.14e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EGF—lung cancer	9.33e-06	8.14e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CG—lung cancer	9.31e-06	8.13e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—APC—lung cancer	9.31e-06	8.13e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KIT—lung cancer	9.31e-06	8.13e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—NRAS—lung cancer	9.31e-06	8.13e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTT1—lung cancer	9.3e-06	8.11e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EGF—lung cancer	9.3e-06	8.11e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTGS2—lung cancer	9.24e-06	8.07e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EGF—lung cancer	9.21e-06	8.03e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP2A6—lung cancer	9.19e-06	8.02e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GCLC—lung cancer	9.19e-06	8.02e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—MAPK3—lung cancer	9.04e-06	7.88e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—MAPK3—lung cancer	9.01e-06	7.86e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—POMC—lung cancer	8.98e-06	7.84e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—POMC—lung cancer	8.95e-06	7.81e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—MAPK3—lung cancer	8.92e-06	7.78e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—BRAF—lung cancer	8.87e-06	7.74e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—POMC—lung cancer	8.87e-06	7.74e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—BRAF—lung cancer	8.84e-06	7.71e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6R—lung cancer	8.76e-06	7.64e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—BRAF—lung cancer	8.75e-06	7.64e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CREBBP—lung cancer	8.75e-06	7.63e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6R—lung cancer	8.73e-06	7.62e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CREBBP—lung cancer	8.72e-06	7.61e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ENO1—lung cancer	8.71e-06	7.6e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PTEN—lung cancer	8.65e-06	7.55e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6R—lung cancer	8.65e-06	7.55e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CREBBP—lung cancer	8.64e-06	7.53e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CB—lung cancer	8.62e-06	7.52e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—EGFR—lung cancer	8.6e-06	7.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—EGFR—lung cancer	8.57e-06	7.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTGS2—lung cancer	8.54e-06	7.45e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—EGFR—lung cancer	8.49e-06	7.4e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAP2K1—lung cancer	8.35e-06	7.29e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAP2K1—lung cancer	8.32e-06	7.26e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CD—lung cancer	8.29e-06	7.24e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CD—lung cancer	8.27e-06	7.21e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—EP300—lung cancer	8.25e-06	7.2e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAP2K1—lung cancer	8.24e-06	7.19e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	8.22e-06	7.17e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	8.19e-06	7.15e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CD—lung cancer	8.19e-06	7.14e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—KRAS—lung cancer	8.12e-06	7.09e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	8.11e-06	7.08e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—KRAS—lung cancer	8.09e-06	7.06e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PTEN—lung cancer	8.06e-06	7.03e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—KRAS—lung cancer	8.02e-06	6.99e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP2E1—lung cancer	7.81e-06	6.82e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—NQO1—lung cancer	7.73e-06	6.74e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—EP300—lung cancer	7.69e-06	6.71e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	7.46e-06	6.51e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PTEN—lung cancer	7.45e-06	6.5e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	7.44e-06	6.49e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MDM2—lung cancer	7.43e-06	6.48e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MDM2—lung cancer	7.41e-06	6.46e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—RAF1—lung cancer	7.41e-06	6.46e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—RAF1—lung cancer	7.38e-06	6.44e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	7.36e-06	6.43e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MDM2—lung cancer	7.34e-06	6.4e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—ERBB2—lung cancer	7.33e-06	6.39e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—RAF1—lung cancer	7.31e-06	6.38e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—ERBB2—lung cancer	7.3e-06	6.37e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—ERBB2—lung cancer	7.23e-06	6.31e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CB—lung cancer	7.23e-06	6.31e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MTOR—lung cancer	7.23e-06	6.31e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MTOR—lung cancer	7.21e-06	6.29e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CB—lung cancer	7.21e-06	6.29e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MTOR—lung cancer	7.14e-06	6.23e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CB—lung cancer	7.14e-06	6.23e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—EP300—lung cancer	7.1e-06	6.2e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—STK11—lung cancer	6.96e-06	6.08e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CXCL8—lung cancer	6.95e-06	6.06e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CXCL8—lung cancer	6.93e-06	6.04e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—HRAS—lung cancer	6.9e-06	6.02e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—HRAS—lung cancer	6.88e-06	6e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CXCL8—lung cancer	6.86e-06	5.98e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—HRAS—lung cancer	6.81e-06	5.95e-05	CbGpPWpGaD
Disopyramide—CHRM1—GPCR downstream signaling—AKT1—lung cancer	6.71e-06	5.86e-05	CbGpPWpGaD
Disopyramide—CHRM3—GPCR downstream signaling—AKT1—lung cancer	6.69e-06	5.84e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CASP3—lung cancer	6.65e-06	5.8e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL2—lung cancer	6.64e-06	5.79e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CASP3—lung cancer	6.63e-06	5.78e-05	CbGpPWpGaD
Disopyramide—CHRM2—GPCR downstream signaling—AKT1—lung cancer	6.63e-06	5.78e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL2—lung cancer	6.62e-06	5.77e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—IL6—lung cancer	6.61e-06	5.76e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—IL6—lung cancer	6.59e-06	5.75e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CASP3—lung cancer	6.56e-06	5.73e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL2—lung cancer	6.55e-06	5.72e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—IL6—lung cancer	6.52e-06	5.69e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CCND1—lung cancer	6.47e-06	5.65e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—JUN—lung cancer	6.46e-06	5.64e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CCND1—lung cancer	6.45e-06	5.63e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTP1—lung cancer	6.44e-06	5.62e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—JUN—lung cancer	6.44e-06	5.62e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CCND1—lung cancer	6.39e-06	5.57e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—JUN—lung cancer	6.38e-06	5.56e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MMP9—lung cancer	6.28e-06	5.48e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CAT—lung cancer	6.27e-06	5.47e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MMP9—lung cancer	6.26e-06	5.47e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—CDKN1A—lung cancer	6.26e-06	5.46e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PTEN—lung cancer	6.25e-06	5.45e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—CDKN1A—lung cancer	6.24e-06	5.45e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PTEN—lung cancer	6.23e-06	5.43e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MMP9—lung cancer	6.2e-06	5.41e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—CDKN1A—lung cancer	6.18e-06	5.39e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PTEN—lung cancer	6.17e-06	5.38e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—PIK3CA—lung cancer	6.1e-06	5.32e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ABCB1—lung cancer	6.1e-06	5.32e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling by GPCR—AKT1—lung cancer	6.09e-06	5.32e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling by GPCR—AKT1—lung cancer	6.08e-06	5.3e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling by GPCR—AKT1—lung cancer	6.02e-06	5.25e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—TYMS—lung cancer	5.99e-06	5.23e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EP300—lung cancer	5.96e-06	5.2e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EP300—lung cancer	5.94e-06	5.18e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—GSTM1—lung cancer	5.92e-06	5.17e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EP300—lung cancer	5.88e-06	5.13e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—SRC—lung cancer	5.79e-06	5.06e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—SRC—lung cancer	5.78e-06	5.04e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—SRC—lung cancer	5.72e-06	4.99e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—PIK3CA—lung cancer	5.69e-06	4.96e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—VEGFA—lung cancer	5.64e-06	4.92e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—VEGFA—lung cancer	5.62e-06	4.91e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CYP1A1—lung cancer	5.61e-06	4.9e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—STAT3—lung cancer	5.59e-06	4.88e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—NRAS—lung cancer	5.57e-06	4.86e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—VEGFA—lung cancer	5.57e-06	4.86e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—STAT3—lung cancer	5.57e-06	4.86e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ERCC2—lung cancer	5.57e-06	4.86e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—NRAS—lung cancer	5.56e-06	4.85e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—STAT3—lung cancer	5.52e-06	4.81e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—NRAS—lung cancer	5.5e-06	4.8e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MAPK3—lung cancer	5.34e-06	4.66e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MAPK3—lung cancer	5.32e-06	4.64e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MAPK3—lung cancer	5.27e-06	4.6e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—PIK3CA—lung cancer	5.25e-06	4.58e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—MYC—lung cancer	5.19e-06	4.53e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—MYC—lung cancer	5.18e-06	4.52e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—MYC—lung cancer	5.13e-06	4.47e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—EGFR—lung cancer	5.08e-06	4.43e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—EGFR—lung cancer	5.06e-06	4.42e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—EGFR—lung cancer	5.01e-06	4.37e-05	CbGpPWpGaD
Disopyramide—SLC22A2—Metabolism—AKT1—lung cancer	4.99e-06	4.35e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—APOA1—lung cancer	4.82e-06	4.2e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—KRAS—lung cancer	4.8e-06	4.19e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—KRAS—lung cancer	4.78e-06	4.17e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—KRAS—lung cancer	4.74e-06	4.13e-05	CbGpPWpGaD
Disopyramide—SLC22A1—Metabolism—AKT1—lung cancer	4.65e-06	4.05e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—PIK3CA—lung cancer	4.41e-06	3.85e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CG—lung cancer	4.4e-06	3.84e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—PIK3CA—lung cancer	4.39e-06	3.83e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—PIK3CA—lung cancer	4.35e-06	3.8e-05	CbGpPWpGaD
Disopyramide—CHRM3—Metabolism—AKT1—lung cancer	4.29e-06	3.75e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—TP53—lung cancer	4.26e-06	3.72e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—TP53—lung cancer	4.25e-06	3.71e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—TP53—lung cancer	4.21e-06	3.67e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—POMC—lung cancer	4.19e-06	3.65e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—HRAS—lung cancer	4.08e-06	3.56e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—CREBBP—lung cancer	4.08e-06	3.56e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—HRAS—lung cancer	4.06e-06	3.55e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—HRAS—lung cancer	4.03e-06	3.51e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—IL6—lung cancer	3.9e-06	3.41e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—IL6—lung cancer	3.89e-06	3.39e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CD—lung cancer	3.87e-06	3.37e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—IL6—lung cancer	3.85e-06	3.36e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—ALB—lung cancer	3.82e-06	3.33e-05	CbGpPWpGaD
Disopyramide—CHRM1—Signaling Pathways—AKT1—lung cancer	3.6e-06	3.14e-05	CbGpPWpGaD
Disopyramide—CHRM3—Signaling Pathways—AKT1—lung cancer	3.59e-06	3.13e-05	CbGpPWpGaD
Disopyramide—CHRM2—Signaling Pathways—AKT1—lung cancer	3.55e-06	3.1e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CB—lung cancer	3.37e-06	2.94e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTGS2—lung cancer	3.34e-06	2.91e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PTEN—lung cancer	2.91e-06	2.54e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—EP300—lung cancer	2.78e-06	2.42e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—PIK3CA—lung cancer	2.05e-06	1.79e-05	CbGpPWpGaD
Disopyramide—CYP3A4—Metabolism—AKT1—lung cancer	1.68e-06	1.46e-05	CbGpPWpGaD
